Comparison 1. Ustekinumab versus placebo.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Failure to maintain clinical remission at 22 weeks	1	145	Risk Ratio (M‐H, Fixed, 95% CI)	0.80 [0.63, 1.02]
2 Failure to maintain clinical response at 22 weeks	1	145	Risk Ratio (M‐H, Fixed, 95% CI)	0.53 [0.36, 0.79]
3 Failure to maintain clinical remission at 44 weeks	1	388	Risk Ratio (M‐H, Fixed, 95% CI)	0.76 [0.64, 0.91]
3.1 90 mg/8 weeks	1	193	Risk Ratio (M‐H, Fixed, 95% CI)	0.73 [0.56, 0.94]
3.2 90 mg/12 weeks	1	195	Risk Ratio (M‐H, Fixed, 95% CI)	0.80 [0.63, 1.03]
4 Failure to maintain clinical response at 44 weeks	1	388	Risk Ratio (M‐H, Fixed, 95% CI)	0.74 [0.60, 0.91]
4.1 90 mg/8 weeks	1	193	Risk Ratio (M‐H, Fixed, 95% CI)	0.73 [0.54, 0.99]
4.2 90 mg/12 weeks	1	195	Risk Ratio (M‐H, Fixed, 95% CI)	0.75 [0.56, 1.00]
5 Adverse events	2	541	Risk Ratio (M‐H, Fixed, 95% CI)	0.94 [0.87, 1.03]
6 Serious adverse events	2	541	Risk Ratio (M‐H, Fixed, 95% CI)	0.74 [0.48, 1.15]
7 Withdrawal due to adverse events	1	145	Risk Ratio (M‐H, Fixed, 95% CI)	4.93 [0.59, 41.18]